5-氟尿嘧啶治疗药物监测的可行性与人群暴露:PREDICT-5FU多中心临床试验
PREDICT-5FU为多中心前瞻性单臂观察研究,纳入50例接受5-FU或卡培他滨的成人癌症患者,评估TDM可行性。基于体表面积给药仅36%达目标AUC,TDM调整后58%达标(绝对提高22%,p=0.03),中位3周期内实现。DPYD变异携带者 upfront减量后均低于目标AUC,1例发生3级毒性。
要点
- 基于体表面积给5-FU仅36%患者达目标AUC,61%低于、3%高于目标范围。
- TDM调整后58%患者达目标AUC,较BSA给药绝对提高22%(p=0.03),中位3周期达标。
- DPYD变异携带者 upfront减量后均低于目标AUC,1例发生3级毒性。
核心结论
- TDM指导5-FU给药可行,可提高达目标AUC的患者比例。
- 结果适用于所有接受5-FU治疗的癌症,尤其对 upfront减量的DPYD变异携带者有意义。
研究设计与样本
- 多中心、前瞻性、观察性单臂研究,在四家澳大利亚医院开展。
- 纳入50例接受5-FU(≥24h输注)或卡培他滨的成人癌症患者,覆盖胃肠、乳腺和头颈癌。
- 连续周期行TDM直至达目标AUC,全部患者行药物基因组检测。
主要发现
- 50例患者中男性24例、女性26例,中位年龄63岁;下消化道癌40%(20/50),转移性疾病80%(40/50)。
- 76%(38/50)接受5-FU,其中多数输注46h。
- 基于BSA给药时仅36%的5-FU患者达目标AUC,61%低于、3%高于目标范围。
- TDM调整后58%患者达目标AUC(较BSA给药绝对提高22%,p=0.03),中位3周期(范围1-5)内实现。
- DPYD变异等位基因携带者(3/4)因杂合性 upfront减量,均低于目标AUC,1例发生3级毒性;UH2/U比值或尿嘧啶血症与DPYD基因型无相关性;TDM结果平均采样后4天报告。
临床怎么用
- 对接受标准剂量5-FU或卡培他滨的患者可开展TDM,以个体化调整剂量提高目标AUC达标率。
- 对DPYD变异携带者 upfront减量后仍需关注暴露不足和毒性风险,TDM有助于后续调整。
局限性
- 单臂观察性设计,样本量50例,未设对照。
- TDM结果平均采样后4天报告,可能影响实时剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: PREDICT-5FU aimed to document 5-fluorouracil (5FU) exposure in a cancer population and to evaluate the feasibility of 5FU and capecitabine therapeutic drug monitoring (TDM) in patients receiving standard doses and schedules. METHODS: Multicentre, prospective, observational single-arm study. Eligible adult patients received 5FU (infusional ≥24 h) or capecitabine. Patients were treated for gastrointestinal, breast and head-and-neck cancers at four Australian hospitals. TDM was performed in consecutive cycles until target area under the curve (AUC) was reached. Pharmacogenetic testing was performed for all patients. RESULTS: Fifty patients (24 males, 26 females) were recruited. Median age was 63 years; common diagnoses were lower gastrointestinal cancers 40% (20/50) and metastatic disease 80% (40/50). The majority received 5FU (38/50, 76%) over 46 h. Only 36% of 5FU patients achieved target AUC when dosed based on body surface area; 61% were below and 3% above target range. Post TDM-adjusted dosing, target AUC was achieved in 58% of patients (22% absolute increase vs. BSA dosing, p = 0.03), within median three cycles (range 1-5). DPYD variant allele carriers (3/4) had upfront reduced dosing due to heterozygosity; all were below the target AUC and one experienced Grade 3 toxicity. There was no correlation between dihydrouracil: uracil ratio [UH2/U] or uracilemia [U] and DPYD genotype. TDM results were reported with an average of 4 days from sampling. CONCLUSION: TDM dosing is feasible and increases the proportion of patients reaching target AUC. Findings are relevant across all cancers treated with 5FU, and particularly for DPYD variant allele carriers receiving upfront dose reductions.
引用
- Glewis S, Michael M, Gurney H, et al. Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial. Br J Clin Pharmacol. 2025. PMID: 39988750. doi:10.1002/bcp.70006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。